The Royal Marsden at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
The Royal Marsden takes part in 27 sessions at ESMO 2026 in Madrid. Its program ranges from personalised melanoma care, including neoantigen selection and lifileucel, to integrated palliative care and ESMO clinical practice guidelines. Other sessions cover new targeted drugs for platinum-resistant ovarian cancer, endocrine therapy in early breast cancer, and immunotherapy around surgery for head and neck cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
The Royal Marsden London, United Kingdom | |
NHS specialist cancer hospital with sites in London and Sutton, England, partnered with the Institute of Cancer Research. | Keynote Fri Oct 23 11:38–11:48 Chair Fri Oct 23 13:30–15:00 Melanoma: From standard fit to bespoke care Melanoma & skin cancers Chair Fri Oct 23 13:30–15:00 Rapid oral: Genitourinary tumours, prostate, penile and testils Genitourinary cancersGastrointestinal cancers Abstract Fri Oct 23 13:45–13:57 Invited Discussant 1209RO, 1210RO and 2217RO Genitourinary cancersGastrointestinal cancers Talk Fri Oct 23 13:50–14:10 Shared and private neoantigen selection: Matchmaking TCRs Melanoma & skin cancers Chair Fri Oct 23 16:15–17:45 Talk Fri Oct 23 16:15–16:20 Introduction Nursing & supportive care Abstract Fri Oct 23 17:00–17:10 Talk Fri Oct 23 17:10–17:25 DC programme overview: Where we are and where we are going Nursing & supportive care Chair Sat Oct 24 10:15–11:45 ESMO Clinical Practice Guidelines 1 Gastrointestinal cancersGynaecological cancers Chair Sat Oct 24 10:15–11:30 Multidisciplinary insights for effective care in gynaecological sarcomas Sarcoma, CNS, head & neck and rare cancers Talk Sat Oct 24 10:15–10:20 Presentation of case/condition Sarcoma, CNS, head & neck and rare cancers Abstract Sat Oct 24 11:20–11:32 Invited Discussant LBA53 and 2045O Genitourinary cancers Satellite Sat Oct 24 13:10–13:20 Impact of Peri operative IO in LA HNSCC: From Biological Rationale to Clinical Outcomes Sarcoma, CNS, head & neck and rare cancers Satellite Sat Oct 24 13:40–14:10 MDT Case Discussion Sarcoma, CNS, head & neck and rare cancers Abstract Sat Oct 24 15:05–15:17 Invited Discussant LBA89 and 3715O Sarcoma, CNS, head & neck and rare cancers Satellite Sat Oct 24 18:30–20:00 Satellite Sat Oct 24 18:30–18:35 Welcome and Introduction Gynaecological cancers Satellite Sat Oct 24 19:15–19:35 Precision in Practice – Navigating Biomarkers and Sequencing Gynaecological cancers Satellite Sat Oct 24 19:35–19:50 Future Directions and Case-Based Application Gynaecological cancers Chair Sun Oct 25 08:30–10:00 Proffered paper: Head and neck cancer Sarcoma, CNS, head & neck and rare cancers Abstract Sun Oct 25 09:38–09:50 Invited Discussant LBA44, LBA45 and 1535O Sarcoma, CNS, head & neck and rare cancers Abstract Sun Oct 25 10:15–10:25 Talk Sun Oct 25 10:15–10:30 Black women's views and experiences of making lifestyle changes following breast cancer treatment Nursing & supportive care Chair Sun Oct 25 10:15–11:45 ESMO Clinical Practice Guidelines 2 Breast cancerGenitourinary cancers Chair Sun Oct 25 10:15–11:15 Talk Sun Oct 25 10:15–10:20 Talk Sun Oct 25 11:05–11:15 Satellite Sun Oct 25 13:00–14:30 Satellite Sun Oct 25 13:00–13:05 Welcome and introduction Breast cancer Satellite Sun Oct 25 13:05–13:25 Chair Sun Oct 25 14:45–16:15 Rapid oral 2: Genitourinary tumours, renal and urothelial Genitourinary cancers Abstract Sun Oct 25 15:54–16:06 Invited Discussant 3593RO, 3594RO and 3595RO Genitourinary cancers Chair Sun Oct 25 16:30–18:00 Rapid oral: Supportive and palliative care Nursing & supportive care Abstract Sun Oct 25 17:45–17:55 Invited Discussant 3087RO, 3088RO, 3898RO Nursing & supportive care Talk Mon Oct 26 09:10–09:30 Chair Mon Oct 26 12:00–12:50 What oncologists should know about interpreting tumour sequencing Biomarkers & precision oncology Talk Mon Oct 26 12:15–12:30 Liquid biopsy and CHIP: What clinicians need to know Biomarkers & precision oncology Satellite Mon Oct 26 13:25–14:00 Real-world experience: Challenges & strategies in treating DTs Sarcoma, CNS, head & neck and rare cancers Chair Mon Oct 26 14:45–16:15 Talk Mon Oct 26 14:45–15:05 Abstract Mon Oct 26 15:43–15:53 Talk Mon Oct 26 15:45–16:05 Local treatments for imatinib-resistant GIST: Implications of broad KIT inhibition Sarcoma, CNS, head & neck and rare cancers Talk Mon Oct 26 15:45–16:05 MRD to inform treatment decision Breast cancer Chair Tue Oct 27 09:00–13:00 |
Instantly find 20 buyers from The Royal Marsden
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction